Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
64
TMO Quote, Financials, Valuation and Earnings
Last price:
$578.82
Seasonality move
:
6.45%
Day range:
$576.33 - $579.81
52-week range:
$385.46 - $610.97
Dividend yield:
0.3%
P/E ratio:
33.46x
P/S ratio:
5.03x
P/B ratio:
4.26x
Volume:
401K
Avg. volume:
1.7M
1-year change:
9.48%
Market cap:
$217.6B
Revenue:
$42.9B
EPS (TTM):
$17.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific, Inc.
|
$10.9B | $5.50 | 4.89% | 35.02% | $639.39 |
|
BDSX
Biodesix, Inc.
|
$21M | -- | 21.59% | -- | $32.50 |
|
GRAL
GRAIL, Inc.
|
$35.4M | -$3.27 | 10.23% | -1.26% | $105.00 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.4B | $1.99 | 12.86% | 19.35% | $599.60 |
|
SHC
Sotera Health Co.
|
$303.7M | $0.22 | 3.04% | 462.3% | $18.93 |
|
VCYT
Veracyte, Inc.
|
$124.9M | $0.32 | 11.04% | 511.28% | $47.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific, Inc.
|
$579.12 | $639.39 | $217.6B | 33.46x | $0.43 | 0.3% | 5.03x |
|
BDSX
Biodesix, Inc.
|
$6.67 | $32.50 | $53.4M | -- | $0.00 | 0% | 6.41x |
|
GRAL
GRAIL, Inc.
|
$91.86 | $105.00 | $3.6B | -- | $0.00 | 0% | 22.69x |
|
ISRG
Intuitive Surgical, Inc.
|
$577.15 | $599.60 | $204.6B | 76.39x | $0.00 | 0% | 21.83x |
|
SHC
Sotera Health Co.
|
$17.70 | $18.93 | $5B | 91.71x | $0.00 | 0% | 4.39x |
|
VCYT
Veracyte, Inc.
|
$42.77 | $47.50 | $3.4B | 112.67x | $0.00 | 0% | 6.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific, Inc.
|
41.15% | 1.043 | 19.57% | 0.96x |
|
BDSX
Biodesix, Inc.
|
102.42% | -0.860 | 120.74% | 1.62x |
|
GRAL
GRAIL, Inc.
|
2.55% | 4.765 | 2.74% | 7.26x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.065 | -- | 3.42x |
|
SHC
Sotera Health Co.
|
80.53% | 0.673 | 50.96% | 1.99x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.341 | 1.49% | 5.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific, Inc.
|
$4.6B | $2.2B | 7.77% | 13.15% | 19.37% | $1.8B |
|
BDSX
Biodesix, Inc.
|
$17.7M | -$7M | -50.62% | -333.87% | -32.36% | -$8.9M |
|
GRAL
GRAIL, Inc.
|
-$17.3M | -$125.3M | -16.4% | -16.84% | -346.17% | -$63.6M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.7B | $759.7M | 16.35% | 16.38% | 30.33% | $735.6M |
|
SHC
Sotera Health Co.
|
$174.5M | $125.4M | 1.98% | 11.79% | 40.29% | $33.4M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
Thermo Fisher Scientific, Inc. vs. Competitors
-
Which has Higher Returns TMO or BDSX?
Biodesix, Inc. has a net margin of 14.58% compared to Thermo Fisher Scientific, Inc.'s net margin of -40.04%. Thermo Fisher Scientific, Inc.'s return on equity of 13.15% beat Biodesix, Inc.'s return on equity of -333.87%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific, Inc.41.29% $4.28 $86.8B BDSXBiodesix, Inc.81.14% -$1.16 $71.2M -
What do Analysts Say About TMO or BDSX?
Thermo Fisher Scientific, Inc. has a consensus price target of $639.39, signalling upside risk potential of 10.41%. On the other hand Biodesix, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 381.48%. Given that Biodesix, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Biodesix, Inc. is more attractive than Thermo Fisher Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific, Inc.17 5 0 BDSXBiodesix, Inc.4 1 0 -
Is TMO or BDSX More Risky?
Thermo Fisher Scientific, Inc. has a beta of 0.899, which suggesting that the stock is 10.144% less volatile than S&P 500. In comparison Biodesix, Inc. has a beta of 0.625, suggesting its less volatile than the S&P 500 by 37.529%.
-
Which is a Better Dividend Stock TMO or BDSX?
Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.3%. Biodesix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.43% of its earnings as a dividend. Biodesix, Inc. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or BDSX?
Thermo Fisher Scientific, Inc. quarterly revenues are $11.1B, which are larger than Biodesix, Inc. quarterly revenues of $21.8M. Thermo Fisher Scientific, Inc.'s net income of $1.6B is higher than Biodesix, Inc.'s net income of -$8.7M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 33.46x while Biodesix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 5.03x versus 6.41x for Biodesix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific, Inc.5.03x 33.46x $11.1B $1.6B BDSXBiodesix, Inc.6.41x -- $21.8M -$8.7M
-
Which has Higher Returns TMO or GRAL?
GRAIL, Inc. has a net margin of 14.58% compared to Thermo Fisher Scientific, Inc.'s net margin of -245.83%. Thermo Fisher Scientific, Inc.'s return on equity of 13.15% beat GRAIL, Inc.'s return on equity of -16.84%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific, Inc.41.29% $4.28 $86.8B GRALGRAIL, Inc.-47.91% -$2.46 $2.3B -
What do Analysts Say About TMO or GRAL?
Thermo Fisher Scientific, Inc. has a consensus price target of $639.39, signalling upside risk potential of 10.41%. On the other hand GRAIL, Inc. has an analysts' consensus of $105.00 which suggests that it could grow by 14.3%. Given that GRAIL, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe GRAIL, Inc. is more attractive than Thermo Fisher Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific, Inc.17 5 0 GRALGRAIL, Inc.2 2 0 -
Is TMO or GRAL More Risky?
Thermo Fisher Scientific, Inc. has a beta of 0.899, which suggesting that the stock is 10.144% less volatile than S&P 500. In comparison GRAIL, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TMO or GRAL?
Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.3%. GRAIL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.43% of its earnings as a dividend. GRAIL, Inc. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or GRAL?
Thermo Fisher Scientific, Inc. quarterly revenues are $11.1B, which are larger than GRAIL, Inc. quarterly revenues of $36.2M. Thermo Fisher Scientific, Inc.'s net income of $1.6B is higher than GRAIL, Inc.'s net income of -$89M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 33.46x while GRAIL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 5.03x versus 22.69x for GRAIL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific, Inc.5.03x 33.46x $11.1B $1.6B GRALGRAIL, Inc.22.69x -- $36.2M -$89M
-
Which has Higher Returns TMO or ISRG?
Intuitive Surgical, Inc. has a net margin of 14.58% compared to Thermo Fisher Scientific, Inc.'s net margin of 28.31%. Thermo Fisher Scientific, Inc.'s return on equity of 13.15% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific, Inc.41.29% $4.28 $86.8B ISRGIntuitive Surgical, Inc.66.36% $1.95 $17B -
What do Analysts Say About TMO or ISRG?
Thermo Fisher Scientific, Inc. has a consensus price target of $639.39, signalling upside risk potential of 10.41%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.89%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific, Inc.17 5 0 ISRGIntuitive Surgical, Inc.14 11 1 -
Is TMO or ISRG More Risky?
Thermo Fisher Scientific, Inc. has a beta of 0.899, which suggesting that the stock is 10.144% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock TMO or ISRG?
Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.3%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.43% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or ISRG?
Thermo Fisher Scientific, Inc. quarterly revenues are $11.1B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Thermo Fisher Scientific, Inc.'s net income of $1.6B is higher than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 33.46x while Intuitive Surgical, Inc.'s PE ratio is 76.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 5.03x versus 21.83x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific, Inc.5.03x 33.46x $11.1B $1.6B ISRGIntuitive Surgical, Inc.21.83x 76.39x $2.5B $709.2M
-
Which has Higher Returns TMO or SHC?
Sotera Health Co. has a net margin of 14.58% compared to Thermo Fisher Scientific, Inc.'s net margin of 15.55%. Thermo Fisher Scientific, Inc.'s return on equity of 13.15% beat Sotera Health Co.'s return on equity of 11.79%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific, Inc.41.29% $4.28 $86.8B SHCSotera Health Co.56.04% $0.17 $2.8B -
What do Analysts Say About TMO or SHC?
Thermo Fisher Scientific, Inc. has a consensus price target of $639.39, signalling upside risk potential of 10.41%. On the other hand Sotera Health Co. has an analysts' consensus of $18.93 which suggests that it could grow by 6.94%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Sotera Health Co., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific, Inc.17 5 0 SHCSotera Health Co.5 3 0 -
Is TMO or SHC More Risky?
Thermo Fisher Scientific, Inc. has a beta of 0.899, which suggesting that the stock is 10.144% less volatile than S&P 500. In comparison Sotera Health Co. has a beta of 1.815, suggesting its more volatile than the S&P 500 by 81.485%.
-
Which is a Better Dividend Stock TMO or SHC?
Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.3%. Sotera Health Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.43% of its earnings as a dividend. Sotera Health Co. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or SHC?
Thermo Fisher Scientific, Inc. quarterly revenues are $11.1B, which are larger than Sotera Health Co. quarterly revenues of $311.3M. Thermo Fisher Scientific, Inc.'s net income of $1.6B is higher than Sotera Health Co.'s net income of $48.4M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 33.46x while Sotera Health Co.'s PE ratio is 91.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 5.03x versus 4.39x for Sotera Health Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific, Inc.5.03x 33.46x $11.1B $1.6B SHCSotera Health Co.4.39x 91.71x $311.3M $48.4M
-
Which has Higher Returns TMO or VCYT?
Veracyte, Inc. has a net margin of 14.58% compared to Thermo Fisher Scientific, Inc.'s net margin of 14.51%. Thermo Fisher Scientific, Inc.'s return on equity of 13.15% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific, Inc.41.29% $4.28 $86.8B VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About TMO or VCYT?
Thermo Fisher Scientific, Inc. has a consensus price target of $639.39, signalling upside risk potential of 10.41%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 11.06%. Given that Veracyte, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Veracyte, Inc. is more attractive than Thermo Fisher Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific, Inc.17 5 0 VCYTVeracyte, Inc.8 2 1 -
Is TMO or VCYT More Risky?
Thermo Fisher Scientific, Inc. has a beta of 0.899, which suggesting that the stock is 10.144% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.
-
Which is a Better Dividend Stock TMO or VCYT?
Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.3%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.43% of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or VCYT?
Thermo Fisher Scientific, Inc. quarterly revenues are $11.1B, which are larger than Veracyte, Inc. quarterly revenues of $131.9M. Thermo Fisher Scientific, Inc.'s net income of $1.6B is higher than Veracyte, Inc.'s net income of $19.1M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 33.46x while Veracyte, Inc.'s PE ratio is 112.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 5.03x versus 6.87x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific, Inc.5.03x 33.46x $11.1B $1.6B VCYTVeracyte, Inc.6.87x 112.67x $131.9M $19.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
